Alzheimer's Anxiety Drug Approval Leads to 57% Revenue Surge; Executive Sells Partial Stake

Axsome Therapeutics, Inc. (NASDAQ: AXSM) reported first-quarter 2026 net product revenue of $191.2 million, up 57% year-over-year, while recording a net loss of $64.5 million. The company closed the quarter with $305.1 million in cash and equivalents. Strong sales of AUVELITY, SUNOSI and SYMBRAVO drove the revenue increase. In April, AUVELITY received FDA approval for the treatment of agitation associated with Alzheimer’s dementia and is scheduled for commercial launch in June. During the same period, Axsome outlined clinical and regulatory plans for its CNS pipeline—including AXS-12, AXS-05 and AXS-20—and noted that its existing cash position is sufficient to fund operations until profitability is achieved.

Concurrent with these results, company executive Mark Coleman sold shares in three tranches on May 29, June 1 and June 2 at around $220 per share, realizing approximately $3.96 million in proceeds under a pre-established Rule 10b5-1 trading plan. Coleman continues to hold a significant direct and indirect equity stake following these transactions.

In late May, Axsome presented additional clinical data on AUVELITY for major depressive disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting and has announced participation in multiple investor conferences to strengthen outreach to institutional investors.

Axsome is a biotechnology company specializing in central nervous system disorders—including depression, agitation in Alzheimer’s dementia, sleep disorders and migraine—with lead products AUVELITY and SUNOSI and follow-on pipeline candidates AXS-05, AXS-12, AXS-14 and AXS-20.